Coleen Glessner - 06 Mar 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Quality & Ethics, and CPL
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
06 Mar 2025
Net transactions value
$0
Form type
4
Filing time
10 Mar 2025, 16:17:20 UTC
Previous filing
04 Mar 2025
Next filing
09 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +62,500 +55% $0.000000 176,656 06 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Options (Right to Buy) Award $0 +62,500 +33% $0.000000 249,613 06 Mar 2025 Common Stock 62,500 $5.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.